Journal
FEMS YEAST RESEARCH
Volume 10, Issue 8, Pages 1060-1069Publisher
OXFORD UNIV PRESS
DOI: 10.1111/j.1567-1364.2010.00665.x
Keywords
therapeutic vaccine; yeast vaccine; immunotherapy; carcinoembryonic antigen; Saccharomyces cerevisiae; antitumor activity
Funding
- Intramural NIH HHS [Z01 BC010661] Funding Source: Medline
Ask authors/readers for more resources
The ultimate goal of therapeutic vaccines is to activate and exploit the patient's own immune system to vigorously and dynamically seek and eradicate established malignant or virally infected cells. Therapeutic vaccines also offer the potential for preventing disease recurrence. Saccharomyces cerevisiae-based vaccines, where the yeast is engineered to express viral or tumor antigens, represent an ideal therapeutic approach due to their ability to stimulate tumor- or viral-specific CD4+ and CD8+ T-cell responses that are capable of reducing disease burden. This review describes preclinical and clinical studies supporting the development of S. cerevisiae-based therapeutic vaccines for the treatment of cancer and viral diseases, as well as multimodal strategies in which therapeutic vaccines are combined with cytotoxic drugs to achieve a greater clinical response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available